Patient Home Monitoring (PHM) Announces January 2012 Growth Figures

Patient Home Monitoring Corp. (TSX VENTURE:PHM), a company focused on in-home
cardiology healthcare services, today announced monthly growth in terms of
meters shipped during the month of January 2012. 


PHM adds patients to their long-term annuity stream business every month,
increasing annual revenue with every new patient.


Monthly Growth 

January 2012 Meter Shipments 

PHM shipped 188 meters in January 2012, the first month of the second quarter
fiscal 2012.




----------------------------------------------------------------------------
                     Meters     Total Meters Shipped (running total) for the
Month (Quarter)     Shipped                                          Quarter
----------------------------------------------------------------------------
October (Q1)            177                                              177
----------------------------------------------------------------------------
November (Q1)           169                                              346
----------------------------------------------------------------------------
December (Q1)           155                   501 total meters shipped in Q1
----------------------------------------------------------------------------
January (Q2)            188                                              188
----------------------------------------------------------------------------



At the end of each month, PHM classifies revenue into two components: 

1. Existing Patient Services: PHM generates a recurring monthly revenue stream
from enrolled weekly testers. 


2. New Patient Enrollment: New patients add to the existing monthly revenue stream. 

Once enrolled, PHM ships a meter with an expected 5-year economic life to a
patient. With this meter investment, PHM generates monthly recurring revenue by
providing weekly monitoring services to the patient. 


Understanding how many meters were shipped to newly enrolled patients each month
is relevant for analyzing growth because shipment of a meter is a prerequisite
to performing INR(1) tests eligible for reimbursement(2). 


"January is typically a slow month in the US healthcare services industry as
patients have large deductibles," said Dr. Jaime Gerber, PHM's CEO. "With the
results from November and December 2011, and January 2012, PHM has exceeded its
expectations in the three slowest months of its year. I look forward to the rest
of the second quarter's growth increasing as we integrate our second clinic
operation and look to close further acquisitions." 


(1) International normalized ratio ("INR") tests are used as measures of current
and future sales performance. Please refer to the "Non-IFRS Measures" section of
PHM's MD&A for further discussion on these operational measures 


(2) Management does not mean to suggest or imply that shipment of meters is
equivalent to revenue. Meter shipment is a prerequisite, but not a guarantee, of
revenue. Management does not propose meter shipments as a non-IFRS financial
measurement, because there is no simple reconciliation between meter shipment
and IFRS revenue.


About PHM 

PHM is a healthcare services company focused on providing home-based monitoring
services and supplies for cardiology patients. PHM's entry-point service
monitors patients on blood thinner medications such as Coumadin(R) or warfarin.
Medicare recently expanded reimbursement for this in-home service. PHM has a
unique value proposition to cardiology groups that manage patients on blood
thinners, focusing on systemization to enroll patients in PST. This unique,
systemized approach creates an opportunity for physician groups to operate more
efficiently, increasing revenue to their clinic while providing a higher
standard of care for patients. PHM plans to lever its position as a value-added
service provider to expand into other home-based services for these patients and
their referring physicians. 


Information in this news release that is not current or historical factual
information may constitute forward-looking information within the meaning of
securities laws. Implicit in this information, particularly in respect of the
future outlook of PHM and anticipated events or results, are assumptions based
on beliefs of PHM's senior management as well as information currently available
to it. While these assumptions were considered reasonable by PHM at the time of
preparation, they may prove to be incorrect. Readers are cautioned that actual
results are subject to a number of risks and uncertainties, including the
availability of funds and resources to pursue operations, decline of
reimbursement rates, changes in US healthcare laws, coverage or budgets,
dependence on few payors, possible new drug discoveries, a novel business model,
dependence on key suppliers, granting of permits and licenses in a highly
regulated business, competition, low profit market segments as well as general
economic, market and business conditions, and could differ materially from what
is currently expected.
(TSXV:INR)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024